BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 26336914)

  • 21. Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma.
    Carrillo-Cruz E; Marín-Oyaga VA; Solé Rodríguez M; Borrego-Dorado I; de la Cruz Vicente F; Quiroga Cantero E; Manzanares Pérez M; Capote FJ; Ramírez Sánchez MJ; Espigado Tocino I; Pérez-Vega H; Vázquez-Albertino R; Pérez-Simón JA
    Eur J Haematol; 2015 Jan; 94(1):23-30. PubMed ID: 24520874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positron emission tomography scanning in the assessment of patients with lymphoma.
    Foo SS; Mitchell PL; Berlangieri SU; Smith CL; Scott AM
    Intern Med J; 2004 Jul; 34(7):388-97. PubMed ID: 15271172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas.
    Li YJ; Li ZM; Xia XY; Huang HQ; Xia ZJ; Lin TY; Li S; Xia Y; Cai XY; Jiang WQ
    J Nucl Med; 2013 Apr; 54(4):507-15. PubMed ID: 23397008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-FDG PET/CT and lung cancer: value of fourth and subsequent posttherapy follow-up scans for patient management.
    Marcus C; Paidpally V; Antoniou A; Zaheer A; Wahl RL; Subramaniam RM
    J Nucl Med; 2015 Feb; 56(2):204-8. PubMed ID: 25613535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.
    Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD
    J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma.
    Zinzani PL; Stefoni V; Tani M; Fanti S; Musuraca G; Castellucci P; Marchi E; Fina M; Ambrosini V; Pellegrini C; Alinari L; Derenzini E; Montini G; Broccoli A; Bacci F; Pileri S; Baccarani M
    J Clin Oncol; 2009 Apr; 27(11):1781-7. PubMed ID: 19273712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of conventional whole-body ¹⁸F-FDG PET/CT in the incidental findings of parotid masses.
    Wang HC; Zuo CT; Hua FC; Huang ZM; Tan HB; Zhao J; Guan YH
    Ann Nucl Med; 2010 Oct; 24(8):571-7. PubMed ID: 20640540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
    J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.
    Huntington SF; Svoboda J; Doshi JA
    J Clin Oncol; 2015 May; 33(13):1467-74. PubMed ID: 25823735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.
    Trotman J; Fournier M; Lamy T; Seymour JF; Sonet A; Janikova A; Shpilberg O; Gyan E; Tilly H; Estell J; Forsyth C; Decaudin D; Fabiani B; Gabarre J; Salles B; Van Den Neste E; Canioni D; Garin E; Fulham M; Vander Borght T; Salles G
    J Clin Oncol; 2011 Aug; 29(23):3194-200. PubMed ID: 21747087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
    Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
    Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hodgkin lymphoma patients in first remission: routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass.
    Dann EJ; Berkahn L; Mashiach T; Frumer M; Agur A; McDiarmid B; Bar-Shalom R; Paltiel O; Goldschmidt N
    Br J Haematol; 2014 Mar; 164(5):694-700. PubMed ID: 24313286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma.
    Zinzani PL; Tani M; Trisolini R; Fanti S; Stefoni V; Alifano M; Castellucci P; Musuraca G; Dalpiaz G; Alinari L; Marchi E; Fina M; Pellegrini C; Farsad M; Cancellieri A; Busca A; Canini R; Pileri S; Baccarani M; Boaron M
    Haematologica; 2007 Jun; 92(6):771-7. PubMed ID: 17550849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up.
    Yapar Z; Kibar M; Yapar AF; Paydas S; Reyhan M; Kara O; Buyukdereli G; Aydin M; Kelle AP; Unal I; Disel U; Yavuz S; Sahin B; Erkisi M
    Nucl Med Commun; 2010 Jan; 31(1):59-66. PubMed ID: 19952921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
    Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. F-18 FDG PET/CT for detection of malignant involvement of peripheral nerves: case series and literature review.
    Bronstein Y; Tummala S; Rohren E
    Clin Nucl Med; 2011 Feb; 36(2):96-100. PubMed ID: 21220969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroid incidentalomas discovered on positron emission tomography CT scanning - Malignancy rate and significance of standardised uptake values.
    Brindle R; Mullan D; Yap BK; Gandhi A
    Eur J Surg Oncol; 2014 Nov; 40(11):1528-32. PubMed ID: 24915858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.